Glenmark Pharmaceuticals Ltd., of Mumbai, India, reported preclinical findings suggesting that GBR 1302 is efficient at eliminating tumor cells and has potential for a large therapeutic window. Unlike current HER2-targeting therapies, GBR 1302 is designed to target both human CD3-epsilon and HER2 and is designed to effectively recruit cytotoxic T lymphocytes against HER2-positive cancer cells, bringing them in close proximity to the tumor cells. Data were presented at the European Society of Medical Oncology Symposium on Immuno-Oncology in Lausanne, Switzerland.